

Revised Draft Agenda
Biocides Working Group Meeting II-2024
10–20 June 2024

The time is indicated in Helsinki time.

10-11 June	10:00-18:00	APCP WG
12 June	10:00-18:00	APCP WG (reserve day)
14 June	10:00-16:00	In-situ
11-13 June	10:00-18:00	TOX WG
14 June	10:00-16:00	In-situ
18 June	10:00-18:00	TOX WG (reserve day)
11 June	10:00-17:00	EFF WG
13 June	10:30-18:00	EFF WG
14 June	10:00-16:00	In-situ
17 June	10:30-18:00	EFF WG
18 June	10:30-13:00	EFF WG (reserve day)
14 June	10:00-16:00	In-situ
17-19 June	10:00-18:00	ENV WG
20 June	10:00-18:00	ENV WG (reserve day)

Analytical methods and physico-chemical properties Working Group

Chair: Andreas Uphoff

Item 1 - Welcome and apologies	<i>For information</i>
Item 2 – Administrative issues	<i>For information</i>
Item 3 – Agreement of the agenda	<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	<i>For information</i>
Item 5 – Agreement on the minutes of WG I 2024	<i>For agreement</i>
Item 6 - Active Substances	
6.1 Early WG on Muscalure (renewal)	<i>For agreement</i>
6.2 Early WG on Active chlorine generated from chloride of ambient water by electrolysis	<i>For agreement</i>
Item 7 – Union Authorisations	
7.1 UA family product containing Transfluthrin PT18	<i>This agenda item will not be discussed as there are no open points.</i>
7.2 UA family product containing L-(+)-lactic acid PT3	<i>This agenda item will not be discussed as there are no open points.</i>
7.3 UA family product containing Chlorocresol PT3	<i>This agenda item will not be discussed as there are no open points.</i>
Item 8– Technical and guidance related items	
8.1 In situ recommendations	<i>For discussion</i>
8.2 ACPG guidance on point 15 of CA-Nov16-Doc.4.3-FinalRev 2 document regarding handling “carriers” in the authorisation of biocidal products	<i>For discussion</i>
8.3 Allocation of pre-soaked wipes to a certain formulation type	<i>For discussion</i>
8.4 Acceptable active substance degradation threshold during storage testing (overdosing)	<i>For discussion</i>
8.5 Worst case commercial packaging for storage testing	<i>For agreement</i>
8.6 TAB entry Role of water in peracetic acid solutions	<i>For agreement</i>
8.7 Waiving of test for self-reactive properties and explosive properties	<i>For discussion</i>
Item 9– AoB	
9.1 Nanomaterials and Biocides	<i>For information</i>
9.2 Review of e-consultations	<i>For information</i>
9.3 Other information	<i>For information</i>

Human Health Working Group Chair: Antero Airaksinen

Item 1 - Welcome and apologies	<i>For information</i>
Item 2 – Administrative issues	<i>For information</i>
Item 3 – Agreement of the agenda	<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	<i>For information</i>
Item 5 – Agreement on the minutes of WG I 2024	<i>For agreement</i>
Item 6 - Active Substances	
6.1 Early WG on in situ generated active bromine - ED assessment	<i>For agreement</i>
6.2 Early WG on Diuron - ED assessment	<i>For agreement</i>
6.3 Early WG on Dazomet renewal	<i>For agreement</i>
6.4 Early WG on chlorate as disinfection by-product in AS applications: * Sodium dichloroisocyanurate (NaDCC) anhydrous PT 2, 3, 4, 5, 11 * Sodium dichloroisocyanurate (NaDCC) dihydrate PT 2, 3, 4, 5, 11 * Trichloroisocyanuric acid (TCCA) PT 2, 3, 4, 5, 11	<i>For agreement</i>
Item 7 – Union Authorisations	
7.1 UA family product containing Transfluthrin PT 18	<i>For agreement</i>
7.2 UA family product containing L-(+)-lactic acid PT 3	<i>This agenda item will not be discussed as there are no open points.</i>
7.3 UA family product containing Chlorocresol PT 3	<i>This agenda item will not be discussed as there are no open points.</i>
7.4 Early WG on UA-APPs containing Icaridine, PT 19	<i>For agreement</i>
7.5 Early WG on QUAT-based products, PT 3, 4	<i>For agreement</i>

Item 8 – Article 75(1)(g) requests

8.1 Early WG on Salicylic acid ED assessment

For agreement

Item 9– Technical and guidance related items

9.1 Cats and pyrethroids - warning sentences

For agreement

9.2 Field of use (HH and EFF joint session)

For discussion

9.3 In situ recommendations

For discussion

Item 10– AoB

10.1 Other information

For information

Efficacy Working Group Chair: Kasia Szymankiewicz

Item 1 - Welcome and apologies

For information

Item 2 – Administrative issues

For information

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

For information

Item 5 – Agreement on the minutes of WG I 2024

For agreement

Item 6 - Union Authorisations

6.1 UA family product containing Transfluthrin PT18

This agenda item will not be discussed as there are no open points.

6.2 UA family product containing L-(+)-lactic acid PT3

This agenda item will not be discussed as there are no open points.

6.3 UA family product containing Chlorocresol PT3

This agenda item will not be discussed as there are no open points.

6.4 Early WG on UA-APPs containing Icaridine, PT19

For agreement

6.5 Early WG on UA-APPs containing peracetic acid, PT2,3,4

For agreement

Item 7 – Article 75(1)(g) requests

7.1 Formic acid, PT6

For agreement

7.2 1,2-Benzisothiazol-3-(2H)-one (BIT), PT6, 13

For agreement

Item 8– Technical and guidance related items

8.1 Resistance draft guidance

For discussion

8.2 TAB proposal – Evaluation of PT 18 products against unicolonial ants

For discussion

8.3 Field of use (HH and EFF joint session)

For discussion

8.4 In situ recommendations

For discussion

8.5 TAB proposal - PT 11 freshwater and/or seawater-based systems

For discussion

Item 9– AoB

9.1 Other information

For information

Environment Working Group Chair: Sander van der Linden

Item 1 - Welcome and apologies

For information

Item 2 – Administrative issues

For information

Item 3 – Agreement of the agenda

For agreement

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

For information

Item 5 – Agreement on the minutes of WG I 2024

For agreement

Item 6 - Active Substances

6.1 Early WG on in situ generated active bromine - ED assessment

For agreement

6.2 Early WG on active chlorine - ED assessment and waiving of data generation

For agreement

6.3 Early WG on Bronopol - Degradation in soil

For agreement

6.4 Early WG on Tosylchloramide sodium - ED assessment

For agreement

6.5 Icaridin - revision of toxicity data

For agreement

Item 7 – Union Authorisations

7.1 UA family product containing Transfluthrin PT18

For agreement

7.2 UA family product containing L-(+)-lactic acid PT3

This agenda item will not be discussed as there are no open points.

7.3 UA family product containing Chlorocresol PT3

This agenda item will not be discussed as there are no open points.

7.4 Early WG on UA-APPs containing Icaridine, PT 19, ERA

For agreement

Item 8 – Article 75(1)(g) requests

8.1 Early WG on Salicylic acid ED assessment

For agreement

Item 9– Technical and guidance related items

9.1 In situ recommendations	<i>For discussion</i>
9.2 Revision of ESD PT 18	<i>For agreement</i>
9.3 Degradation in manure	<i>For agreement</i>
9.4 Qualitative assessment of PAA and HP for releases via the municipal sewer system	<i>For agreement</i>
9.5 TAB entry for PEC soil RA considering NER	<i>For discussion</i>
9.6 Various exposure risk assessment items for agreement	<i>For agreement</i>
9.7 How to model emissions to groundwater from wood preservatives	<i>For agreement</i>

Item 10– AoB

10.1 Other information	<i>For information</i>
------------------------	------------------------